IMPORTANCE Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents.
T reatment of vision impairment from center-involved diabetic macular edema (DME) has evolved from focal/ grid photocoagulation to intravitreous anti-vascular endothelial growth factor (anti-VEGF) therapy. 1 Clinical trials have demonstrated superior visual acuity (VA) and anatomic outcomes for periods of 2 or 5 years in eyes with DME when aflibercept, bevacizumab, or ranibizumab was compared with laser treatment. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The Diabetic Retinopathy Clinical
Research Network (DRCR.net) compared these anti-VEGF agents for DME (Protocol T) 12, 13 ; results demonstrated that 1-and 2-year vision outcomes were similar among the 3 anti-VEGF groups for eyes with entry VA of 20/32 to 20/40. For eyes with baseline VA of 20/50 to 20/320, aflibercept had superior VA outcomes compared with bevacizumab at and over (area under the curve) 2 years. Aflibercept had superior VA outcomes compared with ranibizumab at 1 year, which were no longer present at 2 years, although the area under the curve over 2 years was superior with aflibercept in this subgroup.
14 Several clinical trials have shown that eyes randomly assigned to aflibercept or ranibizumab to manage DME are less likely to experience diabetic retinopathy (DR) worsening and more likely to have DR improvement compared with focal/ grid photocoagulation or observation alone; similar trends on the effects of bevacizumab have been suggested. 2, 3, 6, 7, 9, 11, 15, 16 However, to our knowledge, no data exist comparing the relative effect of these agents on the evolution of DR severity within a randomized clinical trial. This analysis explored those comparisons for DR improvement or worsening through 2 years in a preplanned secondary analysis using data from the DRCR.net Protocol T. 17 
Methods
Study procedures have been reported previously and are summarized briefly herein 12, 13 (protocol available at http://www .drcr.net). Principal eligibility criteria included a single study eye with center-involved DME confirmed by optical coherence tomography and best-corrected electronic VA letter score of 78 through 24 (approximate Snellen equivalent, 20/32 through 20/320). Eyes were not eligible if they had received anti-VEGF treatment within 12 months of enrollment. A total of 660 eyes were randomized 1:1:1 to intravitreous injections of aflibercept, 2.0 mg; bevacizumab, 1.25 mg; or ranibizumab, 0.3 mg. All participants had visits every 4 weeks through week 52. Most eyes were required to receive injections every 4 weeks through week 20. Starting at the 24-week visit, injections were withheld if there was no improvement or worsening in VA and central subfield thickness from the previous 2 consecutive injections, even if the central subfield was 250 μm or more (Stratus equivalent). After week 52, follow-up could be extended to 8-week and then 16-week intervals if injections were deferred at 2 consecutive visits. Injections were resumed if either VA or central subfield thickness worsened by 5 or more letters or 10%, respectively, compared with the last visit or injection. Focal/grid laser was performed starting at week 24 or thereafter if persistent DME was not improving and there were macular areas amenable to photocoagulation. Participants provided written informed consent, and each participant received a $25 gift card at each study visit. The study adhered to the Declaration of Helsinki 18 ;a listing of the institutional review boards that approved the study is given in the eAppendix in the Supplement. Standard 7-field or 4-field-wide digital color fundus photographs were obtained at baseline as well as the 1-year and 2-year visits. Retinopathy severity was evaluated by masked graders at the Fundus Photography Reading Center (76.9% on 7-field and 23.1% on 4-field wide). Changes in DR severity were evaluated in 2 distinct subgroups based on baseline fundus photographs: nonproliferative diabetic retinopathy (NPDR) (Early Treatment Diabetic Retinopathy Study [ETDRS] retinopathy levels 10-53) vs proliferative diabetic retinopathy (PDR) (ETDRS levels 60-85). Ten participants were excluded due to ungradable or unavailable baseline photographs.
Definitions for retinopathy improvement or worsening are summarized in Table 1 . Diabetic retinopathy-worsening events (ie, panretinal photocoagulation, vitrectomy, or anti-VEGF injection [to manage PDR or its complications] , vitreous hemorrhage, retinal detachment, anterior segment neovascularization, or neovascular glaucoma) were collected prospectively. Data from participants who did not have photographs available at the 1-or 2-year visit were excluded from improvement analyses (61 eyes at 1 year; 118 eyes at 2 years). DR severity category. To adjust for potential confounding, separate sensitivity analysis of treatment group comparison was performed that included adjustment for both baseline DR severity and imbalanced baseline characteristics for both improvement and worsening outcomes.
All P values and 95% CIs are 2-sided. The overall type 1 error rate was controlled at 5% using the Hochberg method for multiple treatment group comparisons. 20 No adjustment for analysis of multiple outcomes was performed. SAS, version 9.4 (SAS Institute Inc), was used for statistical analysis.
Results
A total of 650 participants were analyzed. Of these participants, 302 (46.5%) were women, mean (SD) age was 61 (10) years, and 425 (65.4%) participants were white. Nonproliferative DR was present in 495 (76.2%) of the 650 study eyes among participants who had evaluable baseline photographs. Eighteen eyes (3.6%) with a DR severity level of 20 or better were excluded from the improvement analyses since they did not meet the criteria of eyes that were eligible for improvement. 
DR Improvement
Among the eyes with NPDR at baseline, 423 (88.7%) were evaluable for DR improvement at the 1-year visit and 375 (78.6%) were evaluable for DR improvement at the 2-year visit. At the 1-year visit ( Table 2 , Figure 1A ), 44 eyes (31.2%) in the aflibercept group, 29 eyes (22.1%) in the bevacizumab group, and 57 eyes (37.7%) in the ranibizumab group had DR improvement (adjusted difference for aflibercept-bevacizumab, 11.7%; 95% CI, 2.9% to 20.6%; P = .004; adjusted difference for ranibizumab vs bevacizumab, 8.9%; 95% CI, 1.7% to 16.1%; P = .01; and adjusted difference for aflibercept-ranibizumab, 2.9%; 95% CI, −5.7% to 11.4%; P = .51). At the 2-year visit, 33 eyes (24.8%) in the aflibercept group, 25 eyes (22.1%) in the bevacizumab group, and 40 eyes (31.0%) in the ranibizumab group had DR improvement; no treatment group differences were identified. A post hoc subgroup analysis of NPDR eyes with more severe levels of NPDR (levels 47 and 53) at baseline showed higher rates of improvement, varying from 51.9% to 64.6% at 1 year (n = 188), which were fairly stable at 2 years (n = 169), without any treatment group differences at either time point (eFigure 1 in the Supplement). Among the 111 participants with level 35 through 53 DR at baseline who improved at 1 year and had gradable photographs at the 1-and 2-year visits, 66 (59.5%) eyes maintained DR improvement at the 2-year visit (sustained improvement), including 20 (50.0%) among the aflibercept group, 16 (72.7%) among the bevacizumab group, and 30 (61.2%) among the ranibizumab group (P = .74). Only 30 eyes among the 253 (11.9%) eyes with gradable photographs at the 1-and 2-year visits that had not improved at 1 year improved at the 2-year visit (11 [12.8%] eyes in the aflibercept group, 9 [10.2%] in the bevacizumab group, and 10 [12.7%] in the ranibizumab group). Improvement of DR among the 100 eyes with PDR level 61 or greater at baseline could be assessed in 93 eyes (93.0%) Sensitivity analyses, including comparisons of 2-year DR improvement rates, using last observation carried forward for participants with only 1-year photographs (eTable 3 in the Supplement), and comparisons of 2-step or more photographic improvement rates only among participants with gradable photographs (eTable 4 in the Supplement) were consistent in magnitude and direction with the findings reported for the NPDR and PDR subgroups. The comparisons between treatment groups adjusting for baseline imbalanced factors also yielded similar conclusions. The overall rates of DR improvement combining NPDR and PDR groups are provided in eTable 5intheSupplement. Figure 2A provides the cumulative probabilities of DR worsening by treatment group among eyes with NPDR at baseline. At the 1-year visit, rates of worsening were less than 5% in all groups. Worsening rates slowly continued to increase, but no treatment group differences were observed at the 2-year visit (Table 3) , with rates of worsening at 10.2% for the aflibercept 95% CI, 0.65-3.79; P = .54). A post hoc subgroup analysis of the 218 eyes with moderate-severe or severe NPDR (level 47 or 53) at baseline resulted in 2-year cumulative rates of worsening of 18.3% (11 eyes) in aflibercept eyes, 12.9% (7 eyes) in bevacizumab eyes, and 6.5% (5 eyes) in ranibizumab eyes (eFigure 2 A, Nonproliferative DR at baseline. The respective levels of significance for the pairwise comparisons at the 1-year and 2-year visits were aflibercept vs bevacizumab, P = .004 and P = .85; aflibercept vs ranibizumab, P = .51 and P = .85; and ranibizumab vs bevacizumab, P =.01 and P = .85. B, Proliferative DR at baseline. The respective levels of significance for the pairwise comparisons at the 1-year and 2-year visits were aflibercept vs bevacizumab, P < .001 and P =.01; aflibercept vs ranibizumab, P =.02 and P = .06; and ranibizumab vs bevacizumab, P = .09 and P = .73. Error bars indicate 95% CIs. A, Nonproliferative DR at baseline. The respective levels of significance for the pairwise comparisons through the 2-year visit were aflibercept vs bevacizumab, P = .99; aflibercept vs ranibizumab, P = .54; and ranibizumab vs bevacizumab, P = .54. B, Proliferative DR at baseline. The respective levels of significance for the pairwise comparisons through the 2-year visit were aflibercept vs bevacizumab, P = .70; aflibercept vs ranibizumab, P = .70; and ranibizumab vs bevacizumab, P =.62.
DR Worsening
in the Supplement). eTable 6 in the Supplement reports the distribution of the specific events that initially triggered categorization as worsening of DR. Among eyes with NPDR at baseline, vitreous hemorrhage was the initial worsening event in the majority (9 [56.3%]) of the 16 aflibercept eyes, while a 2-step progression of DR severity shown on photographs accounted for 5 (35.7%) and 6 (54.5%) of the worsening events for the 14 bevacizumab and 11 ranibizumab eyes, respectively. However, 6 of the 17 eyes that worsened by the 1-year visit (2 in each anti-VEGF arm) and 16 of the 41 eyes that worsened by the 2-year visit (6 eyes in the aflibercept group, 6 eyes in the bevacizumab group, and 4 eyes in the ranibizumab group) met more than 1 criterion of DR worsening. Four (<1%) eyes developed neovascularization on photographs at 1 year and 12 (2.4%) eyes developed neovascularization on photographs at 2 years. Figure 2B shows the cumulative probability of DR worsening by treatment group among eyes with PDR at baseline. Rates of worsening were higher for eyes with PDR than NPDR. The cumulative probability of worsening by the 2-year visit was 17.2% for the aflibercept group, 26.4% for the bevacizumab group, and 17.6% for the ranibizumab group. No statistically significant differences between treatment groups (Table 3) were identified (adjusted HR for aflibercept vs bevacizumab, 0.70; 95% CI, 0.29-1.69; P = .70; adjusted HR for ranibizumab vs bevacizumab, 0.57; 95% CI, 0.20-1.65; P = .62; and adjusted HR for aflibercept vs ranibizumab, 1.22; 95% CI, 0.44-3.42; P = .70). Vitreous hemorrhage was the initial event indicating DR worsening in most eyes, irrespective of drug assignment (eTable 6 in the Supplement), although during follow-up, 12 of the 31 eyes that worsened by the 2-year visit had more than 1 type of event consistent with DR worsening (including 2 eyes among the aflibercept group, 7 eyes among the bevacizumab group, and 3 eyes among the ranibizumab group).
Sensitivity analyses restricting the NPDR and PDR analysis cohorts to participants who had gradable photographs at the 1-and 2-year visits (eTable 3 in the Supplement) and restricting the worsening criteria to photographic documentation of 2-step or more worsening (eTable 7 in the Supplement) showed similar results. No significant differences in conclusions from the secondary analyses, including additional adjustment for baseline risk factors, were identified. eTable 5 in the Supplement presents the overall cumulative probabilities of DR worsening combining NPDR and PDR groups. There was an association between the total mean number of injections and DR improvement (P < .001 combining all treatment groups), which was similar across treatment groups. Among the more limited number of eyes that had PDR, no significant associations between the total number of injections and DR improvement were identified at the 1-and 2-year visits.
Discussion
Findings from this preplanned secondary analysis of changes in DR are consistent with previous studies that have identified improvement in DR and low rates of DR worsening in eyes actively managed with repeated intravitreous injections of anti-VEGF agents for DME, even in the absence of monthly fixed dosing. 2, 3, [5] [6] [7] 9, 11, 15, 16, 21 The present study expands on those findings suggesting that improvement rates can differ among aflibercept, bevacizumab, and ranibizumab when following our treatment protocol. In this trial, most patients (76.2%) had NPDR. Although an improvement of 2 or more levels on the ETDRS retinopathy scale occurred with each anti-VEGF agent, treatment with aflibercept or ranibizumab was more likely to be associated with improvement at 1 year compared with bevacizumab among eyes with NPDR ( Figure 1A , Table 2 ).
19 At the 2-year visit, no differences in DR improvement rates were identified in eyes with NPDR between the 3 anti-VEGF agents. In the limited number of eyes with PDR at baseline, improvement was more common with aflibercept compared with either bevacizumab or ranibizumab at each of the 2 annual visits ( Figure 1B , Table 2 ). The greater improvement rates associated with aflibercept compared with the other anti-VEGF agents among the small group of eyes with PDR at baseline is consistent with other observations within this trial, specifically, the interaction between VA outcomes and baseline VA or central subfield thickness on optical coherence tomography. Among eyes with more severe disease (ie, worse VA, thicker central subfield thickness, or PDR at baseline), aflibercept had more favorable VA and anatomic outcomes, particularly at 1 year. Despite a reduced number of injections, on average, in the second year of treatment, approximately two-thirds of all eyes that manifested improvement at 1 year continued to manifest improvement at the 2-year visit, irrespective of baseline DR status or treatment group. An association between a greater number of intravitreous injections and improvement was identified among the eyes with NPDR, but the number and frequency of injections that may promote, optimize, and sustain this outcome cannot be ascertained from this trial. Most importantly, whether anatomic improvement in DR status has clinical relevance for outcomes that subsequently affect visual function remains unknown. This possibility is being explored in a DRCR.net trial evaluating the prevention of PDR or DME with vision loss comparing aflibercept with sham injections in eyes with moderately severe to severe NPDR and no DME at baseline.
22
The rates of DR worsening were relatively small across all 3 agents, with no significant differences identified. Nevertheless, some patients receiving anti-VEGF therapy for DME experience worsening of DR, warranting regular surveillance for worsening DR.
Limitations and Strengths
Limitations of this analysis include the finite follow-up period of 2 years, higher-than-ideal numbers of missed visits, and annual visits without gradable photographs. Fewer ranibizumab eyes had 1-or 2-year photographs among the eyes with PDR compared with aflibercept and bevacizumab. The number of patients with PDR and the severity of their disease was limited, and DR severity at baseline was not a stratification factor for randomization. In addition, there were treatment group imbalances in potentially important baseline factors, including baseline DR. However, all statistical analyses adjusted for baseline DR and sensitivity analyses that were adjusted for other potential confounding factors produced similar results. Composite definitions for worsening or improvement did not include investigator determination of DR severity level or data from fluorescein angiography, including ultrawide field images. Some strengths of this analysis include prospective, standardized data collection after the secondary analysis was planned, defined treatment regimens for administration of the anti-VEGF drugs, relatively large numbers of participants, random anti-VEGF assignment, masked grading of photographs, and inclusion of PDR worsening events that are not always readily apparent on fundus images in the composite outcome.
Conclusions
At 1 and 2 years, eyes with NPDR receiving anti-VEGF treatment for DME may experience improvement in DR severity. Less improvement was demonstrated with bevacizumab at 1 year than with aflibercept or ranibizumab. In the smaller subgroup of eyes with PDR at baseline, more improvement with aflibercept was identified at 1 and 2 years. All 3 anti-VEGF treatments were associated with low rates of DR worsening. These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME.
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Googe J, Brucker AJ, Bressler NM, et al; Diabetic
Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009-1027. Protocol T study. Protocol T provided crucial data comparing the 3 most commonly used antivascular endothelial growth factor (VEGF) agents in the management of diabetic macular edema. 2 The authors use the 2-year prospective data on diabetic macular edema treatment to compare the relative efficacy of aflibercept, ranibizumab, and bevacizumab on another clinically relevant end point: diabetic retinopathy (DR) severity. Although evidence already exists to support the use of anti-VEGF therapy in macular edema, this analysis reaffirms prior studies. The authors demonstrate DR improvement in 22.1% of patients in the bevacizumab group, 31.2% in the aflibercept group, and 37.7% of patients in the ranibizumab group at the year 1 visit. Aflibercept and ranibizumab in year 1 proved to be superior to bevacizumab regarding percent of eyes experiencing improvement in DR severity (adjusted difference: 12% [95% CI: 3% to 21%] for afliberceptbevacizumab; adjusted difference: 9% [95% CI: 2% to 16%] for ranibizumab-bevacizumab). These impressive findings persisted into the second year of the study. At the year 2 visit, however, the between-group treatment differences neutralized (adjusted difference: 3% [95% CI: -3% to 9%] for aflibercept-bevacizumab; adjusted difference: 2% [95% CI: -4% to 9%] for ranibizumab-bevacizumab). Aflibercept was significantly better than bevacizumab and ranibizumab in improving proliferative DR, although the sample population was small.
5.
Perhaps equally important, only 7% to 10% of the patients in this study experienced a worsening of nonproliferative DR severity during the study period. The implications of these findings cannot be overstated. Prior to the advent of anti-VEGF therapy, our options for delaying DR progression were limited. The Action to Control Cardiovascular Risk in Diabetes 3 and
Fenofibrate Intervention and Event Lowering in Diabetes 4 studies showed reductions in the progression of DR severity with the institution of intensive glycemic control (hemoglobin A 1c level <6.0%) and treatment of concomitant dyslipidemia. However, in practice, achieving this level of systemic control can prove daunting for patients outside a clinical trial setting. The Centers for Disease Control and Prevention reports that the mean hemoglobin A 1c ranges from 7.2% to 7.7% among adults diagnosed with diabetes in the United States. 5 The recent evidence supporting anti-VEGF therapy for DR treatment represents a paradigm shift in the management of diabetic eye disease. The strengths of this DRCR.net study are numerous. Although originally meant to investigate the effect on diabetic macular edema, the investigators' preplanned secondary analysis was an invaluable addition. The prospective design, large data set, and rigorous study protocol provide the authors with high-quality data to support their conclusions. The transition to 8-and then 16-week intervals in year 2 mirrors the realworld setting. This study also provides strong evidence that bevacizumab is comparable to aflibercept and ranibizumab regarding retinopathy worsening. However, it also affirmed that the 2 US Food and Drug Administration-approved agents, ranibizumab and aflibercept, proved superior to bevacizumab in preventing progression of DR at 1 year, but not at 2 years.
Despite our improving understanding of the key role of anti-VEGF therapy in treating DR, important questions remain. * The protocol specifies 1-year visit as a protocol visit occurring 51 to 53 weeks from randomization, and 2-year visit as one occurring 103 to 105 weeks from randomization.
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** For the purpose of the analysis of DR worsening, a visit completed between 44-60 weeks (308-420 days) was defined as "1-year visit", and a visit completed between 88-120 weeks (616-840 days) was defined as "2-year visit". If multiple visits fell within the same analysis window, the protocol visit closest to the target date was used. ‡ One NPDR participant in aflibercept group completed an out-of-window 1-year visit thus was considered "missed" (as shown in the table). For the purpose of the analysis, however, the gradable photograph that was collected at that visit was included in the analyses of improvement and worsening outcomes. † Among 14 eyes that had non-gradable photographs at 1 year, none met the worsening outcome prior to 1 year. § Among 31 eyes that had non-gradable photographs at 2 years, 1 NPDR eye met the worsening outcome during first year, 2 NPDR eyes and 1 PDR eye met the worsening outcome prior to 2 years by manifesting complications of PDR. 6 (6.7, 9.0) 7.6 (6.7, 8.9) 7.7 (6.6, 8.8) 7.6 (6.6, 8.7) 7.9 (7.0, 9.3) 8.0 (6.9, 9.3)
Prior DME Treatment, N (%) Abbreviation: HbA1c = hemoglobin A1C; DME = diabetic macular edema; ETDRS = Early Treatment Diabetic Retinopathy Study; VEGF = vascular endothelial growth factor; OCT = optical coherence tomography; NPDR = non-proliferative diabetic retinopathy; PRP = panretinal photocoagulation; PDR = proliferative diabetic retinopathy.
* Missing HbA1C data for 4 NPDR completers and 1 PDR completer in the aflibercept group. § Missing central subfield thickness data for 2 NPDR completers in the aflibercept group, 2 NPDR completers in the bevacizumab group, and 1 NPDR completer and 2 PDR completers in the ranibizumab group. † The baseline DR severity levels of NPDR eyes labelled as prior PRP by investigator are 43 (aflibercept), 43 (bevacizumab), and 47 (ranibizumab) at the reading center. 
